The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase 1b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection†
Open accessAbstract
Interferon lambda 1 (IFN-λ1) is a type III IFN that produces intracellular responses similar to those of IFN-α but in fewer cell types because of differences in the receptor distribution pattern, and this could potentially result in an improved safety profile. This was an open-label three-part study of patients with chronic hepatitis C virus (HCV) genotype 1 infection. Part 1 evaluated single-agent pegylated interferon lambda (PEG-IFN-λ) at 1.5 or 3.0 μg/kg administered every 2 weeks or weekly for 4 weeks in patients who had relapsed after previous IFN-α-based treatment. Part 2 evaluated weekly doses of PEG-IFN-λ ranging from 0.5 to 2.25 μg/kg in combination with ribavirin (RBV) for 4 weeks in treatment-relapse patients. Part 3 evaluated weekly PEG-IFN-λ at 1.5 μg/kg in combination with RBV for 4 weeks in treatment-naive patients. Fifty-six patients were enrolled: 24 patients in part 1, 25 patients in part 2, and 7 patients in part 3. Antiviral activity was observed at all PEG-IFN-λ dose levels (from 0.5 to 3.0 μg/kg). Two of seven treatment-naive patients (29%) achieved rapid virological response. Treatment was well tolerated with minimal flu-like symptoms and no significant hematologic changes other than RBV-associated decreases in hemoglobin. The most common adverse events were fatigue (29%), nausea (12%), and myalgia (11%). Six patients experienced increases in aminotransferases that met protocol-defined criteria for dose-limiting toxicity (DLT) or temporarily holding therapy with PEG-IFN-λ. Most DLT occurred in patients with high PEG-IFN-λ exposure. Conclusion: Weekly PEG-IFN-λ with or without daily RBV for 4 weeks is well tolerated with minimal adverse events and hematologic effects and is associated with clear antiviral activity across a broad range of doses in patients with chronic HCV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain
Donnelly, R. P., Sheikh, F., Kotenko, S. V., & Dickensheets, H. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0204117 · Cited by 289
Cited by
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Prokunina-Olsson, L., Muchmore, B., Tang, W., Pfeiffer, R. M., Park, H., Dickensheets, H., Hergott, D., Porter-Gill, P., Mumy, A., Kohaar, I., et al. (2013) · Nature Genetics · doi:10.1038/ng.2521 · Cited by 928
Decoding type I and III interferon signalling during viral infection
Mesev, E. V., LeDesma, R. A., & Ploss, A. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0421-x · Cited by 538
Galani, I. E., Triantafyllia, V., Eleminiadou, E.-E., Koltsida, O., Stavropoulos, A., Manioudaki, M., Thanos, D., Doyle, S. E., Kotenko, S. V., Thanopoulou, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.025 · Cited by 477
Interferon-Lambda: A New Addition to an Old Family
Donnelly, R. P., & Kotenko, S. V. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0078 · Cited by 420
Guarding the frontiers: the biology of type III interferons
Wack, A., Terczyńska-Dyla, E., & Hartmann, R. (2015) · Nature Immunology · doi:10.1038/ni.3212 · Cited by 364
Induction and function of type I and III interferon in response to viral infection
Levy, D. E., Marié, I. J., & Durbin, J. E. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.11.001 · Cited by 314
Interferon-λ orchestrates innate and adaptive mucosal immune responses
Ye, L., Schnepf, D., & Staeheli, P. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0182-z · Cited by 266
Interferons: Success in anti-viral immunotherapy
Lin, F.-C., & Young, H. A. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.015 · Cited by 254
Mullish, B. H., Kabir, M. S., Thursz, M. R., & Dhar, A. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12925 · Cited by 144
Metadata
- Authors
- Muir, A. J., Shiffman, M. L., Zaman, A., Yoffe, B., de la Torre, A., Flamm, S., Gordon, S. C., Marotta, P., Vierling, J. M., Carlos Lopez-Talavera, J., Byrnes-Blake, K., Fontana, D., Freeman, J., Gray, T., Hausman, D., Hunder, N. N., & Lawitz, E.
- Venue
- Hepatology
- Published
- 2010-09
- Volume
- 52
- Issue
- 3
- Pages
- 822-832
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1988025623
- Cited by
- 249
- References
- 1
- FWCI
- 25.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.